LONDON, Feb. 20, 2018 -- The global competent cells market will grow at a CAGR of 10% during the forecast period to reach USD 2,318.6 million by 2023, primarily driven by “growing demand for recombinant proteins and molecular cloned products, advancement in molecular cloning research with emergence of new technologies, various government initiatives, and growing funding for life science research,” Meticulous Research™ noted in a press release today.
Request Sample Report: https://www.meticulousresearch.com/request-sample-report/?cp_id=3723
The report notes that cloned competent cells held the largest share, owing to “their rising adoption in research with increasing feasibility of genetic therapy, growing need for rapid diagnosis & treatment, favorable government support for cloning based research in various countries, and rising availability of sophisticated instruments and technology.”
Geographically, North America held the largest share in this market, due to ”its well-established healthcare system, higher acceptance of advanced technologies, raising non-communicable diseases & related rise in pharmaceutical research & development, increase in cloning based research, favorable reimbursement scenario, and presence of key players in this market.”
The key players in this market are Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Merck & Company, Inc., Illumina, Inc., Promega Corporation, New England Biolabs, OriGene Technologies, Inc., Zymo Research Corporation, Scarab Genomics, LLC, Meridian Bioscience, Inc., Delphi Genetics S.A., Qiagen N.V., Cell Applications, Inc., GenScript Biotech Corporation, and Takara Holdings Inc.
Browse in-depth report on: https://www.meticulousresearch.com/product/competent-cells-market-forecast-2023/
Report Scope:
Type:
- Cloned Competent Cells
- Agrobacterium tumefaciens Competent Cells
- Expression Competent Cells
Treatment:
- Chemically Competent Cells
- Electrocompetent Cells
Application:
- Cloning
- Subcloning & Routine Cloning
- Toxic/Unstable DNA Cloning
- High-Throughput Cloning
- Phage Display Library production
- Protein Expression
- Others
- Single Stranded DNA Preparation
- Mutagenesis Study
- Large Plasmid Transformation
- Lentiviral Vector Production
End User:
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Contract Research Organizations
Geographic scope:
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Turkey
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- Japan
- China
- India
- South Korea
- Australia
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Enquire before buying: https://www.meticulousresearch.com/enquire-before-buying/?cp_id=3723
Contact Info:
Viren Shrivastava
Email: [email protected]
Direct Lines: +1-646-781-8004 (North America)
+44-203-868-8738 (Europe)
+91 744-7780008 (Asia-Pacific)


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Washington Post Publisher Will Lewis Steps Down After Layoffs
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Instagram Outage Disrupts Thousands of U.S. Users
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 



